<div id="readability-page-1"><p>Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT - Get Free Report) have been assigned an average recommendation of &#34;Moderate Buy&#34; from the eight analysts that are presently  covering the stock, Marketbeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, four have issued  a buy recommendation and one  has given a strong buy recommendation to  the company. The average 1-year price target among brokers that have updated their coverage on the stock in the last year is $100.20.</p><div><p><span></span><span>Get <strong>LeMaitre Vascular</strong> alerts:</span></p></div><p>Several equities research analysts have commented on the stock. Zacks Research raised shares of LeMaitre Vascular from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a report on Friday, November 7th. Roth Capital  reissued a &#34;buy&#34; rating and issued a $108.00 price objective on shares of LeMaitre Vascular in a report on Wednesday, November 5th. Wells Fargo &amp; Company lowered their target price on LeMaitre Vascular from $97.00 to $93.00 and set an &#34;equal weight&#34; rating on the stock in a research note on Friday, November 7th. Weiss Ratings upgraded LeMaitre Vascular from a &#34;hold (c+)&#34; rating to a &#34;buy (b-)&#34; rating in a research report on Monday. Finally, Wall Street Zen downgraded LeMaitre Vascular from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, December 6th.</p><p><b>Check Out Our Latest Stock Report on LMAT</b></p><h2>LeMaitre Vascular Price Performance</h2><p>Shares of NASDAQ LMAT opened at $85.27 on Friday. LeMaitre Vascular has a 52 week low of $71.42 and a 52 week high of $105.55. The business's 50 day moving average price is $86.26 and its 200 day moving average price is $87.18. The company has a quick ratio of 11.45, a current ratio of 13.58 and a debt-to-equity ratio of 0.44. The firm has a market cap of $1.93 billion, a P/E ratio of 36.75, a P/E/G ratio of 2.10 and a beta of 0.68. </p><p>LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last announced its quarterly earnings data on Thursday, November 6th. The medical instruments supplier reported $0.62 EPS for the quarter, beating the consensus estimate of $0.57 by $0.05. The business had revenue of $61.05 million during the quarter, compared to analysts' expectations of $62.18 million. LeMaitre Vascular had a net margin of 22.14% and a return on equity of 14.06%. The business's quarterly revenue was up 11.4% compared to the same quarter last year. During the same period in the previous year, the business posted $0.49 EPS. LeMaitre Vascular has set its FY 2025 guidance at 2.480-2.530 EPS and its Q4 2025 guidance at 0.640-0.690 EPS.  On average, sell-side analysts expect that  LeMaitre Vascular will post 1.94 earnings per share for the current year. </p><h2>LeMaitre Vascular Dividend Announcement</h2><p>The company also recently declared a quarterly dividend, which was paid on Thursday, December 4th. Investors of record on Thursday, November 20th were issued a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, November 20th. This represents a $0.80 dividend on an annualized basis and a yield of 0.9%. LeMaitre Vascular's dividend payout ratio  is 34.48%. </p><h2>Institutional Inflows and Outflows</h2><p>A number of institutional investors and hedge funds have recently added to or reduced their stakes in LMAT. Tudor Investment Corp ET AL purchased a new stake in shares of  LeMaitre Vascular during the 3rd quarter worth about $6,056,000.  CIBC Bancorp USA Inc. acquired a new position in  LeMaitre Vascular in the 3rd quarter worth about $799,000.  Advisory Services Network LLC acquired a new position in  LeMaitre Vascular in the 3rd quarter worth about $98,000.  PharVision Advisers LLC purchased a new position in  LeMaitre Vascular during the third quarter worth approximately $355,000.  Finally, Verition Fund Management LLC grew its holdings in  LeMaitre Vascular by 136.2% in the third quarter. Verition Fund Management LLC now owns 16,907 shares of the medical instruments supplier's stock valued at $1,480,000 after purchasing an additional 9,750 shares during the period. Hedge funds and other institutional investors own  84.64% of the company's stock. </p><h2>About LeMaitre Vascular</h2> (Get Free Report)<p>LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than LeMaitre Vascular</li><li>How to buy stock: A step-by-step guide for beginners </li><li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li><li>What Does a Stock Split Mean? </li><li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li><li>Stock Market Sectors: What Are They and How Many Are There? </li><li>MongoDB Could Hit Record Highs—But You’ll Need to Move Fast</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TE1BVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="600" height="385" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9TE1BVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in LeMaitre Vascular Right Now?</h2><p>Before you consider LeMaitre Vascular, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LeMaitre Vascular wasn't on the list.</p><p>While LeMaitre Vascular currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

LMAT

<p>LeMaitre Vascular, Inc. (NASDAQ:LMAT) has received a consensus "Moderate Buy" rating from eight analysts. The stock has a 1-year price target of $100.20. Recent analyst actions include upgrades and downgrades, with a mix of hold, buy, and strong buy ratings. The company reported better-than-expected quarterly earnings and has set future EPS guidance. Institutional investors have been active in adjusting their stakes in the company. LeMaitre Vascular develops and markets medical devices for vascular surgery.</p>

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Receives Consensus Rating of "Moderate Buy" from Brokerages